R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

US vs EU: How can Europe translate home-grown innovation int...

We have seen a boom in biotech initial public offerings over the last two years, but many of Europe’s offerings have migrated to the United States.

Patients

3D Illustration Concept of Human Urinary System Kidneys Anatomy

Chronic kidney disease: treating a silent killer

In November, NICE backed NHS use of AstraZeneca’s diabetes and heart failure drug Forxiga for the treatment of chronic kidney disease.

Views & Analysis

Oslo Medicines Initiative asks how to balance innovation inc...

Access to medicines is “one of the most challenging policy areas in every country in the European region” – it’s time to develop a solution that works for everyone.

Digital

CVS Health and Microsoft alliance: an example of an extended...

Microsoft and CVS Health have announced a new strategic alliance focusing on personalised care and accelerating digital transformation for the benefit of CVS customers and its employees.

R&D

Female child therapist in an office during a phone call, using online calendar to schedule patients appointments. Calendar Planner Organization Management Concept.

Decentralised trials: beyond the pandemic

The adoption of decentralised activities was a major factor in allowing clinical trials to continue during the early stages of the pandemic.

Patients

The evolution of clinical trials: the pharmaphorum podcast

In the latest episode of the pharmaphorum podcast, Dr Paul Tunnah speaks to head of Patient Engagement at Syneos Health, Marie Emms, and Elligo Health Research vice president, strategic partnership

US vs EU: How can Europe translate home-grown innovation int...

Chronic kidney disease: treating a silent killer

Oslo Medicines Initiative asks how to balance innovation inc...

CVS Health and Microsoft alliance: an example of an extended...

Decentralised trials: beyond the pandemic

The evolution of clinical trials: the pharmaphorum podcast

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

Views & Analysis

Editor's Picks